Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADVANCE pediatric obesity platform trial of oral orforglipron
MOH_2024-11-26_013763Phase 3Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in obesity and Overweight comparing orforglipron MTD once daily with placebo once daily (2 arms). Started Nov 2024; status: recruiting.
02
Drugs
orforglipron
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on MOH_2024-11-26_013763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-11-26_013763.